New Adjuvant Technologies for Next-Generation Vaccines
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 11344
Special Issue Editor
Special Issue Information
Dear Colleagues,
This pandemic and post-pandemic brave new world is facing the crude reality of current vaccine technologies (reality being the gigantic effort taken to develop the vaccines that allow us to be protected against SARS-CoV-2/COVID-19). Most of these vaccines were developed based on “in use” or traditional technologies, being protective of mortality but not morbidity or contagion. The mRNA vaccines developed were an exception, representing a promising platform that rapidly developed during the COVID-19; however, they also did not protect completely against infection. In the search for fully protective and more effective vaccines, the development of new adjuvant technologies must be of paramount importance in future vaccines. Not only prophylactic, but also therapeutics vaccines are currently evolving in new treatments by the development of novel adjuvant technologies. In this context, new materials and compounds, such as those from vegetal and fungal origin (that are new, or come to replace classic lipid vehicles), are promising future adjuvants. In this Special Issue of Pharmaceutics, “New Adjuvant Technologies for Next-Generation Vaccines”, we have the opportunity to broadcast to the finest audience our scientific efforts on the research of adjuvant systems that can overcome current vaccine limitations, in the effort of strengthening public health worldwide.
Dr. Darío Lirussi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adjuvant systems
- antigen delivery
- signaling molecules
- plant-derived compounds
- TLR agonists
- PAMP
- molecular adjuvants
- vaccine platforms
- liposomes
- particles in suspension
- immunomodulators
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.